Unknown

Dataset Information

0

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.


ABSTRACT: To observe the effect on total liver volume (TLV) on and off therapy in selected symptomatic patients with autosomal dominant polycystic kidney disease (ADPKD) or autosomal dominant polycystic liver disease (PLD) who received octreotide long-acting release (OctLAR) for up to 4 years.Twenty-eight of 42 participants in a prospective 2-year clinical trial of OctLAR (40 mg monthly) consisting of double-blind, randomized (year 1) and open-label treatment (year 2) phases reenrolled in a 2-year open-label extension (OLE) study after being off OctLAR a mean of 8.3 months (original study: July 1, 2007, through June 30, 2013). Participants underwent magnetic resonance imaging at baseline, years 1 and 2, reenrollment, and study completion. Primary end point: change in TLV; secondary end points: changes in total kidney volume, glomerular filtration rate, quality of life (QoL), safety, vital signs, and laboratory parameters.Twenty-five participants (59.5%) completed the OLE. Off therapy, TLVs increased a mean ± SD of 3.4%±8.2% per year; after resuming therapy, TLVs decreased a mean ± SD of -4.7%±6.1% per year. Despite regrowth off treatment, overall reductions were observed, with a median (interquartile range) TLV of 4047 mL (3107-7402 mL) at baseline and 3477 (2653-7131 mL) at study completion (-13.2%; P<.001) and with improved health-related QoL. Total kidney volumes increased, and glomerular filtration rates declined from 58.2 mL/min to 54.5 mL/min (n=16) in patients with ADPKD on therapy from baseline to study completion.Therapy with OctLAR over 4 years in selected patients with symptomatic PLD arrested PLD progression, alleviating symptoms and improving health-related QoL. Discontinuation led to organ regrowth.clinicaltrials.gov Identifier: NCT00426153.

SUBMITTER: Hogan MC 

PROVIDER: S-EPMC4928579 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.

Hogan Marie C MC   Masyuk Tetyana T   Bergstralh Eric E   Li Bill B   Kremers Walter K WK   Vaughan Lisa E LE   Ihrke Angela A   Severson Amanda L AL   Irazabal Maria V MV   Glockner James J   LaRusso Nicholas F NF   Torres Vicente E VE  

Mayo Clinic proceedings 20150709 8


<h4>Objective</h4>To observe the effect on total liver volume (TLV) on and off therapy in selected symptomatic patients with autosomal dominant polycystic kidney disease (ADPKD) or autosomal dominant polycystic liver disease (PLD) who received octreotide long-acting release (OctLAR) for up to 4 years.<h4>Patients and methods</h4>Twenty-eight of 42 participants in a prospective 2-year clinical trial of OctLAR (40 mg monthly) consisting of double-blind, randomized (year 1) and open-label treatment  ...[more]

Similar Datasets

| S-EPMC5623438 | biostudies-other
| S-EPMC7480539 | biostudies-literature
| S-EPMC10243760 | biostudies-literature
| S-EPMC3433774 | biostudies-literature
| S-EPMC10103320 | biostudies-literature
| S-EPMC6371583 | biostudies-literature
| S-EPMC5545165 | biostudies-literature
| 2233976 | ecrin-mdr-crc
| S-EPMC4609826 | biostudies-literature
| S-EPMC3240834 | biostudies-literature